Patricia Shi, MD (she/her/hers)

Vice-President
New York Blood Center
Rye, New York

Was the first to study using plerixafor mobilization for HPC collection for gene therapy in sickle cell disease.
Has R21 looking at ways to manipulate the gene therapy product to improve engraftment.

Disclosure information not submitted.

Presentation(s):

• AM25-ST-14-L - Allogeneic Transplant, Gene Therapy, or the Evolving Drug Landscape in Sickle Cell Disease: Helping Patients Choose Between Options

  Saturday, October 25, 2025
  10:45 AM - 12:15 PM  PT

• AM25-TU-19-L - What's New in Transfusion Therapy for Sickle Cell Disease

  Tuesday, October 28, 2025
  11:15 AM - 12:15 PM  PT